Humoral factors in serum as predictors of therapeutic response to tumor necrosis factor inhibitors in rheumatoid arthritis
Monitoring serum humoral factors may offer valuable insights into the likelihood of therapeutic success of TNFi in patients with RA. IL-6 rebound at 14 weeks might serve as an early indicator of non-responsiveness to TNFi. These findings highlight the potential of personalized treatment strategies for RA based on serum humoral factor profiling. Larger prospective studies are needed to validate these results and elucidate the underlying mechanisms.
Authors
- Yasuyuki Kamata (ORCID: https://orcid.org/0000-0002-8174-3038)
- Keisuke Saito (ORCID: https://orcid.org/0000-0002-2293-9743)
- Kojiro Sato (ORCID: https://orcid.org/0000-0003-4105-3726)
- Takeo Sato (ORCID: https://orcid.org/0000-0002-2059-9327)
- S. Minota
- Shotaro Yamamoto
- Takao Nagashima (ORCID: https://orcid.org/0000-0003-0620-6774)
Institutions
- Jichi Medical University (JP)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1111/1756-185x.15413
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Japan Society for the Promotion of Science